James Ho
Internal Medicine · Jamaica, NYNPI 1891701223
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 330 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,202 and has fallen 60.1% since, to $878 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $25.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Gilead$2K
- Viiv Healthcare Company$1K
- AbbVie$903
- Janssen Products, LP$576
- Alkermes, Inc.$359
- plus $2K from 22 others
What the payments were for
- Food & beverage$8,14298%
- Education$1822%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 76 | $1,856 |
| Gilead | 65 | $1,609 |
| Viiv Healthcare Company | 47 | $1,138 |
| AbbVie | 39 | $903 |
| Janssen Products, LP | 5 | $576 |
| Alkermes, Inc. | 18 | $359 |
| Teva Pharmaceuticals USA, Inc. | 12 | $305 |
| Neurocrine Biosciences, Inc. | 13 | $297 |
| Indivior Inc. | 6 | $199 |
| Merck | 10 | $199 |
| Dynavax Technologies Corporation | 2 | $124 |
| Theratechnologies Inc. | 7 | $119 |
| E.r. Squibb & Sons, L.L.C. | 3 | $82 |
| Mylan Specialty L.p. | 4 | $82 |
| Lilly USA, LLC | 3 | $81 |
| Otsuka America Pharmaceutical, Inc. | 4 | $77 |
| Ascensia Diabetes Care US Inc. | 4 | $68 |
| Lundbeck LLC | 2 | $44 |
| Mannkind Corporation | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| GSK | 1 | $23 |
| Exact Sciences | 1 | $23 |
| EMD Serono, Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Napo Pharmaceuticals Inc | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $16 |
| Orexo US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,324 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 36 | $149,039 |
| DovatoDolutegravir Sodium/Lamivudine | 39 | $114,191 |
| VraylarCariprazine Hcl | 46 | $71,296 |
| RelistorMethylnaltrexone Bromide | 19 | $49,006 |
| EntrestoSacubitril/Valsartan | 56 | $37,700 |
| EliquisApixaban | 59 | $34,404 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $33,378 |
| TrulicityDulaglutide | 32 | $30,285 |
| RexultiBrexpiprazole | 20 | $28,434 |
| JanumetSitagliptin Phos/Metformin Hcl | 34 | $20,814 |
| JanuviaSitagliptin Phosphate | 28 | $15,924 |
| JardianceEmpagliflozin | 19 | $11,964 |
| OzempicSemaglutide | 12 | $11,291 |
| BrilintaTicagrelor | 19 | $8,188 |
| FarxigaDapagliflozin Propanediol | 12 | $7,003 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $1,609 | $149,03936 claims |
| Viiv Healthcare CompanyDovato | $1,138 | $114,19139 claims |
| AbbVieVraylar | $903 | $71,29646 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $22 | $49,00619 claims |
| MerckJanumet, Januvia | $199 | $36,73862 claims |
| GSKTrelegy Ellipta | $23 | $33,37853 claims |
| Lilly USA, LLCTrulicity | $81 | $30,28532 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $77 | $28,43420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Jamaica
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.